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The importance ofNaV1.7 (encodedby SCN9A) in the regulationof pain sensing is exemplifiedby theheterogeneity of clinical phenotypes
associated with its mutation. Gain-of-function mutations are typically pain-causing and have been associated with inherited eryth-
romelalgia (IEM) and paroxysmal extreme pain disorder (PEPD). IEM is usually caused by enhancedNaV1.7 channel activation, whereas
mutations that alter steady-state fast inactivation often lead to PEPD. In contrast, nonfunctional mutations in SCN9A are known to
underlie congenital insensitivity to pain (CIP). Although well documented, the correlation between SCN9A genotypes and clinical phe-
notypes is still unclear.Herewe report three familieswithnovelSCN9Amutations. Inamultiaffecteddominant familywith IEM,we found
the heterozygous change L245 V. Electrophysiological characterization showed that this mutation did not affect channel activation but
instead resulted in incomplete fast inactivation and a small hyperpolarizing shift in steady-state slow inactivation, characteristics more
commonly associatedwithPEPD. In two compoundheterozygousCIPpatients, we foundmutations that still retained functionality of the
channels, with two C-terminal mutations (W1775R and L1831X) exhibiting a depolarizing shift in channel activation. Two mutations
(A1236E and L1831X) resulted in a hyperpolarizing shift in steady-state fast inactivation. To our knowledge, these are the first descrip-
tions of mutations with some retained channel function causing CIP. This study emphasizes the complex genotype–phenotype correla-
tions that exist for SCN9A andhighlights the C-terminal cytoplasmic region ofNaV1.7 as a critical region for channel function, potentially
facilitating analgesic drug development studies.
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Introduction
Naturally occurring mutations in SCN9A have been linked with
both hyposensitive and hypersensitive pain states, emphasizing
the important role of the encoded ion channel NaV1.7 in the
regulation of nociceptive neuron excitability (Dib-Hajj et al.,
2013). Gain-of-function mutations in SCN9A are linked with
debilitating, chronic pain syndromes, typified by inherited eryth-
romelalgia (IEM), paroxysmal extreme pain disorder (PEPD),
and small-fiber neuropathy (SFN). IEM and PEPD are rare but
clinically distinct conditions; IEM is characterized by an episodic
burning sensation in the hands and feet that is often coupled with
redness and swelling, whereas PEPD is associated with extreme
bouts of pain within proximal regions of the body, typically rectal
and ocular. Patientswith idiopathic SFNpresentwithmorewide-
spread axonal degeneration resulting in pain and other sensory
impairments, and a recent report found SCN9Amutations in 8 of
28 affected individuals (Faber et al., 2012). Loss-of-functionmu-
tations, by contrast, have been associated with a complete ab-
sence of pain in affected individuals, a condition known as
congenital insensitivity to pain (CIP).
Electrophysiological characterization has revealed that, like
other voltage-gated sodium channels, Nav1.7 shows voltage-
dependent activation and inactivation, with the latter having fast
and slow components. Known SCN9A-associated CIPmutations
are incapable of supporting functional NaV1.7 expression, sug-
gesting a crucial role of this current for nociception (Cox et al.,
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2006, 2010) and the essential dependence of nociception on
Nav1.7was recently confirmed inmice (Gingras et al., 2014). SFN
mutations appear to impair the slow inactivation of Nav1.7 cur-
rents, and it has been suggested that the resulting overexcitability
results in an increased sensitivity of small-diameterDRGneurons
to otherwise benign insults (Faber et al., 2012). Overexcitability is
also observed when mutations found in patients with IEM or
PEPD are heterologously expressed inDRGneurons (Dib-Hajj et
al., 2008; Estacion et al., 2008; Eberhardt et al., 2014); however,
the underlying electrophysiological characteristics of the mutated
NaV1.7 are thought to differ from each other. IEM mutations gen-
erally cause a hyperpolarizing shift in channel activation, whereas
PEPD is typically associated with a depolarizing shift in fast inacti-
vation (albeit often incomplete), resulting in persistent and/or
resurgent currents. Why, or how, subtle changes in channel gat-
ing result in different phenotypes is currently unclear, but rare
mutations found in patients with mixed IEM and PEPD symp-
toms have been shown to simultaneously display altered activa-
tion and inactivation properties (Estacion et al., 2008).
To further understand the effects of discrete molecular and
functional changes in both hyposensitive and hypersensitive
pain conditions, we electrophysiologically characterized four
novel mutations in NaV1.7 identified in two individual cases
of CIP (W1775R, A1236E, L1831X) and one case of IEM
(L245V). Surprisingly, all three CIP-related mutations gave
rise to functional NaV1.7 channels, exhibiting changes in acti-
vation and/or fast inactivation gating properties, coupled with
a significant reduction in total current. In contrast, the single
IEM-related mutation showed no change in channel activa-
tion properties but did show significant changes in inactiva-
tion properties. Our results challenge a simple correlation
between electrophysiological properties observed in vitro and
patient phenotype.
Materials andMethods
Identification of novel SCN9A mutations. The cases reported here were
sequentially ascertained from a British National Health Service molecu-
lar genetics laboratory service offering Mendelian pain gene sequencing.
Cases of either sex referred to our service have both excess or lack of
pain phenotypes, and SCN9A is one of the human genes we routinely
screen. Genomic DNA was isolated from peripheral blood by stan-
dard methods. All coding exons and flanking splice sites of SCN9A
were bidirectionally sequenced using previously reported primers
(Cox et al., 2006).
Construction of expression plasmids.Thewild-type SCN9A-polio IRES-
DsRed2 construct (FLRED) and the SCN1B-encephalomyocarditis virus-
SCN2B-polio IRES-EGFP (JC5) construct were generated as previously
described (Cox et al., 2006). These bear either SCN9A and DsRed2
(FLRED) or SCN1B, SCN2B, and EGFP (JC5) on the same vector ex-
pressed from the same promoter, and the inclusion ofDsRed2 and EGFP
in these constructs helped in the identification of positively cotransfected
cells when patch clamping. The Nav1.7-L245V, Nav1.7-A1236E, Nav1.7-
A1632E, Nav1.7-W1775R, and Nav1.7-L1831X mutations were intro-
duced into FLRED using the QuikChange II XL Site-Directed
Mutagenesis Kit (Stratagene) or by recombinant PCR.
Cell culture and transfection. HEK293 cells were used for all experi-
ments. Briefly, HEK293 cells were maintained in a 75 cm2 flask with
DMEM (4500 mg/L glucose) supplemented with 5% FBS, L-glutamine,
and penicillin/streptomycin (culture medium) at 37°C, 5% CO2. Cells
were split every third day of culture. For transfection, HEK293 cells were
plated directly onto 35mmplastic dishes (Falcon) and incubated for 24 h
at 37°C, 5% CO2. After 24 h, the culture medium was replaced and the
cells were incubated for 30 min. After 30 min, 500 l of Optimem (In-
vitrogen) containing 1 g of SCN9A cDNA (mutant or wild-type), 42.5
ng of 1/2 cDNA, and 10 l of lipofectamine 2000 (Invitrogen) was
added to each dish of cells, which were then incubated for 24 h at 37°C,
5%CO2. For the negative control, 1/2 cDNA (42.5 ng) was transfected
alone. After 24 h, the cells were split and diluted 1:20 in culture medium
and plated directly onto 35 mm dishes and incubated for 24 h. All cells
were recorded from 24 to 48 h after transfection.
Electrophysiological analysis. All electrophysiological recordings were
performed using an AxoPatch 200B amplifier and a Digidata 1440A
digitizer (Axon Instruments), controlled by Clampex software (version
10, Molecular Devices). Filamented borosilicate microelectrodes
(GC150TF-15, Harvard Apparatus) were coated with beeswax and fire
polished using a microforge (Narishige) to give resistances of 2–3 M.
For voltage-clamp experiments, the following solutions were used. Ex-
tracellular solution (values are in mM) as follows: 140 NaCl, 3 KCl, 1
MgCl2, 2 CaCl2, 10 HEPES, 1 glucose, pH 7.4 with NaOH. Intracellular
solution (values in mM) as follows: 107 CsF, 10 EGTA, 10 TEA.Cl, 2
MgCl2, 10 HEPES, 10 NaCl, 1 CaCl2, pH 7.2 with CsOH. Unless other-
wise stated, standard whole-cell currents were acquired at 25 kHz and
filtered at 10 kHz (low-pass Bessel filter) at 22°-24°C. After achieving
whole-cell configuration, a holding potential of 100 mV was applied
and series resistance was compensated by 70%. All currents were leak
subtracted using a p/4 protocol. Liquid junction potentials were calcu-
lated using Clampex software and corrected for before analysis. For
resurgent current recordings, the4 peptide (KKLITFILKKTREK, Invit-
rogen) was included in the intracellular pipette solution at 100 M. The
peptide was added on the day of experiment from a 10 mM stock
(ddH2O). Voltage-dependent activation was fitted to a Boltzmann equa-
tion y (A2 (A1A2)/(1 exp((Vh x)/k)))  (xVrev), whereA1
is the maximal amplitude,Vh is the potential of half-maximal activation,
x is the clampedmembrane potential,Vrev is the reversal potential, and k
is a constant. Voltage dependence of inactivation was fitted to a single
Boltzmann equation: y  (A1  A2)/(1  exp((x  Vh/k))  A2, or a
double Boltzmann equation: y y0A  ( frac/(1 exp((x x01)/ k1))
 (1 frac)/(1 exp((x x02)/k2))), where k1 and k2were constrained
to 4.5. All Boltzmann equations were fitted using Origin software. Volt-
age dependence of channel deactivation was fitted to a double exponen-
tial of the form: f(t)  Af exp (t/f)  As exp (t/s)  C, using
Clampfit software.
Data analysis. All electrophysiological data were extracted using
Clampfit (version 10, Molecular Devices) and analyzed using Origin 9.0
(OriginLab). Significance was determined at p 0.05. Individual p val-
ues are given for each comparison made.
Results
Identification of novel SCN9Amutations and patient
phenotype
A large family with an inherited erythromelalgia phenotype and
two unrelated individuals with apparent congenital insensitivity
to pain were referred to us for genetic testing (for location of
novel mutations in NaV1.7, see Fig. 1).
Family 1. The index case referred to us suffered from severe
episodic pain in his hands and feet associated with excess heat
perception. Three other members of the family were similarly
affected andanother five cases suspectedaccording to familyhistory.
The painful episodes usually became distressing in the second de-
cadeof lifebut retrospectively startedapproximatelyadecadeearlier.
Episodes were precipitated by exercise, hot weather, and viral ill-
ness, and soothed by cold. Attacks usually started with pain re-
stricted to the surface of the affected body part, but later during
an episode pain was also perceived deeper within the tissue; dur-
ing an attack, the affected part of the body exhibited allodynia and
erythema, but this was not usually accompanied by swelling. The
episodes tended to get more frequent and of greater severity with
age; however, familymembers have developed a number of strat-
egies to minimize the number and severity of the attacks, such as
exercising in bare feet and wearing open sandals. Attacks could
reliably be aborted by cooling within the first 5 min, but not
thereafter. The pain phenotype was inherited as a dominant trait,
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with both males and females similarly af-
fected and passage from mother to son
and father to daughter. Other possible
causes of erythromelalgia had previously
been excluded; and importantly, none of
the affected family members reported
pain on defecating or in facial (ocular) ar-
eas. We found the novel heterozygous
SCN9A change c.733CG (causing the
NaV1.7 change p.L245V) in the referred
index case. We thence confirmed that
three other clinically affected individuals
bore the mutation, whereas one clinically
unaffected individual who requested test-
ing did not.
Family 2. The index case was a 5-year-
old girl referred to us as having no evi-
dence of feeling pain. She had not shown
any signs of distress during early life’s im-
munizations or teething but lacked any
injuries to her lips, tongue, or terminal
digits often seen in other individuals with
congenitally inherited insensitivity to
pain. However, the parents became con-
cerned that she failed to respond appro-
priately to repeated falls and minor
injuries, culminating with her developing a limp when 3 years of
age andbeing found to have a fractured femur. She complained of
no pain during this episode, and once placed in a plaster cast the
bone healed normally. As speech developed, she was able to ar-
ticulate that she did not feel discomfort or pain after injuries or
falls but realized that other people found these events unpleasant.
Her development and general health were normal. We tested the
patient by applying pressure with a rigid 0.8 cm plastic tube onto
the proximal region of the nail bed of the index finger while the
patient’s hand lay flat on a hard unyielding surface. This proce-
dure does not result in lasting damage to the nail or bruising, but
control individuals report touch sensation at gentle pressures
applied, which disappears immediately upon removal of the
weight and pain lasting 10 s when the applied weight exceeds
1 kg. The patient, by contrast, could perceive pressure but did
not report any unpleasant sensation at maximal applied weights
exceeding 10 kg. The patient was also anosmic. Screening of
SCN9A identified two mutations, which were inherited from her
parents, who each also carried a wild-type allele and had normal
pain perception. The mutations identified are a mutation in the
canonical splice donor site of exon 7 from GTATG to GTATC
c.901 5GC expected to give rise to misplicing, which would
be expected to trigger nonsense mediated decay and a missense
SCN9A mutation c.5323TA (causing the NaV1.7 change
p.W1775R).
Family 3. The index case was a 12-year-old boy, who had been
adopted at age 6 and his prior early history was unknown.He had
always appeared to have a high pain tolerance responding little to
injuries and accidents, while being intolerant of others distress.
He had accumulated a number of scars from injuries on his limbs,
had burn scars on his hand, and a chronic long-standing injured
ankle that had never properly healed (a Charcot’s joint). His
intelligence and general health appeared normal. He is anosmic
and did not report to feel any pain when pressure was applied to
the nail bed of his index finger (see above). Screening of SCN9A
identified two mutations, a missense mutation c.3707CA
(causing the NaV1.7 change p.A1236E) and the nonsense muta-
tion c.5492TG (causing the NaV1.7 change p. L1831X). This
latter nonsense mutation occurred in the terminal exon of
SCN9A and would be expected to lead to a stable mRNA prod-
uct and a prematurely truncated protein missing the
C-terminal 146 amino acids of the protein. Subsequent
screening of the birth parents genotype was not possible.
Characterization of novel CIP-associated mutations
To further understand the link betweenmolecular and functional
changes in NaV1.7 channels in the CIP cases, electrophysiological
analysis was performed on three of the mutations identified in
Families 2 and 3: W1775R, A1236E, and L1831X. Individual pa-
rameter comparisons are summarized in Table 1. Rather intrigu-
ingly, all three mutants gave rise to functional channels, giving
averaged peak activation currents of 115.9 	 15.0,  41.0 	
11.9, and 103.3 	 14.0 pA/pF for W1775R, A1236E, and
L1831X, respectively (Fig. 2A–F). The peak activation currents
from mutant channels were significantly smaller than the peak
current for WT NaV1.7 (361 	 39.5 pA/pF); however, they
were substantially bigger than the 1/2 negative control (8.9	
1.1 pA/pF). With respect to gating properties, the Vh of channel
activation for W1775R and L1831X was shifted significantly to
more depolarized potentials (13.4	 1.3 and15.4	 1.8 mV,
respectively) compared with WT (25.2 	 1.6 mV), whereas
A1236E exhibited no significant shift (21.5 	 1.8 mV). In ad-
dition, the steepness of the voltage dependence, k, was signifi-
cantly shallower for W1775R (7.5 	 0.2), A1236E (7.3 	
0.4), and L1831X (7.6	 0.2) compared withWT (3.7	 0.3).
No change in reversal potential (Vrev) was observed betweenWT,
mutant, or1/2 negative control currents, consistent withNa
-
selective currents. Analysis of fast inactivation properties showed
that A1236E and L1831X exhibited a hyperpolarizing shift in Vh
values (80.7 	 1.3 and 82.2 	 1.3 mV, respectively) com-
pared withWT (71.1	 1.3 mV), whereas no significant differ-
ence was observed with W1775R (73.4 	 2.2 mV) (Fig.
2B,D,F). In addition, there was a significant difference in the
slope k of channel inactivation for W1775R (11.6 	 1.1),
Figure 1. Location of characterized CIP and IEM-associated mutations in NaV1.7. Schematic representation of NaV1.7 showing
the 24 trans-membrane (TM) domains contained within four regions (DI-IV). Within each region, there are six TM domains. The
fourth TM domain within each region acts as the voltage sensor (red), whereas TM domains 5 and 6 come together to form the
channel pore (green). The proposed location for each mutation is shown. Y163X (CIP) is located within the second TM domain of
the first region (not studied). L245V (IEM) is located within the intracellular loop between domains 4 and 5 of the first region.
A1236E (CIP) is located within the second TM domain of the third region. W1775R (CIP) and L1831X (CIP) are both located within
the intracellular C-terminal tail.
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A1236E (9.1 	 0.8), and L1831X (7.9 	 0.6), compared with
WT (6.1 	 0.4).
Characterization of a novel IEM-associated mutation
Electrophysiological analysis was performed on the IEM-
associated NaV1.7 mutation, L245V. Individual parameter com-
parisons are summarized in Table 1. Analysis of channel
activation properties showed that L245V gave rise to functional
channels and exhibited peak activation currents that were not
significantly different toWT (398.5	 44.7 and361.2	 39.5
pA/pF, respectively; Fig. 3A). Furthermore, L245V and WT acti-
vation currents exhibited almost identicalVh values (25.2	 1.3
and 25.2 	 1.6 mV, respectively), with Vrev values also being
comparable. There was, however, a modest, but significant,
change in the slope (k) for L245V (4.9 	 0.4) compared with
WT (3.7	 0.3). Fast inactivation properties were also investi-
gated for L245V. In contrast to WT, L245V fast inactivating cur-
rents were fitted with a double Boltzmann, with the firstVh value
(Vh#1;71.2	 0.6mV) of the double Boltzmann fit being similar
toVh forWT currents (71.1	 1.3 mV) (Fig. 3B). Interestingly,
L245V currents exhibited incomplete fast inactivation, leaving a
substantial persistent current remaining even 500 ms following
initial channel activation at several test pulses (Fig. 3B,D), and it
is likely that the inability of L245V channels to fully undergo fast
inactivation allows a secondary slower inactivation process with
rightward shifted voltage dependence to become apparent. In
addition to incomplete fast inactivation, L245V also exhibited a
significant hyperpolarizing shift in the Vh of slow inactivation
(L245V: 41.4 	 0.9 mV; WT: 31.4 	 1.8 mV), a slowing of
deactivation kinetics (L245V: 0.20	 0.02ms;WT: 0.09	 0.1 ms
at60 mV), as well as an increased ramp current in response to
a depolarizing ramp stimulus (Fig. 3E–G). We next investigated
whether the changes in channel inactivation associated with
L245V give rise to the emergence of resurgent currents by includ-
ing the 4 peptide (KKLITFILKKTREK; 100 M) in the intracel-
lular pipette solution. We were, however, unable to detect clear
resurgent currents beyond the observed tail currents in the ab-
sence of the -4 peptide for the wild-type, the L245V mutation,
or the previously described A1632E mutation (Fig 3C).
Discussion
Given the fundamental role of NaV1.7 ion channels in pain, un-
derstanding howmolecular and functional changes affect sensory
nerve function could facilitate the development of novel analge-
sics, as well as improve current treatment strategies for related
chronic pain syndromes. In this study, we identified and electro-
physiologically characterized four naturally occurring novel mu-
tations in NaV1.7 that give rise to either hyposensitive (CIP) or
hypersensitive (IEM) pain conditions.
The link between NaV1.7 functional change and pathogenesis
Previous studies have concluded that pain-insensitive mutations
are due to a total loss of NaV1.7 channel function (Cox et al.,
2006, 2010; Ahmad et al., 2007), which, given the fundamental
role of NaV1.7 in regulating electrical activity in sensory neurons,
intuitively explains the painless phenotype. Here, however, we
present three novel CIP-associated mutations in NaV1.7 that all
retain some functionality. Electrophysiological characterization
of the three mutations showed that each had a significant reduc-
tion in peak current following activation, compared withWT. In
addition, each mutation also exhibited changes in activation
and/or inactivation properties. BothW1775R and L1831X exhib-
ited an10mV depolarizing shift in channel activation, whereas
A1236E and L1831X exhibited a similar hyperpolarizing shift in
channel fast inactivation. Such changes in channel activation/
inactivation properties would have the effect of reducing the
number of channels activated, as well as reducing the number of
channels available for activation, respectively, which would ulti-
Table 1. Summary of channel gating parameters for WT andmutant NaV1.7 channels
a
WT W1775R A1236E L1831X L245V 1 /2 only
Activation
V0.5 (mV) 25.2	 1.6 13.4	 1.3,
p 5.24E-4
21.5	 1.8 15.4	 1.8,
p 1.50E-3
25.2	 1.3 30.3	 4.9
k 3.7	 0.3 7.5	 0.2,
p 1.54E-6
7.3	 0.4,
p 3.54E-6
7.6	 0.2,
p 1.30E-7
4.9	 0.4,
p 2.16E-2
9.5	 1.2,
p 6.72E-7
VRev (mV) 67.5	 2.3 71.4	 4.9 67.5	 3.8 72.5	 5.3 74.0	 3.1 76.9	 15.5
Imax (pA.pF
1) 361.2	 39.5 115.9	 15.0,
p 2.24E-3
41.0	 11.9,
p 5.75E-5
103.3	 14.0,
p 3.73E-4
398.5	 44.7 8.9	 1.1,
p 1.18E-4
n 23 7 8 9 16 6
Fast inactivation
V0.5 (mV) 71.1	 1.3 73.4	 2.2 80.7	 1.3,
p 3.22E-4
82.2	 1.3,
p 2.82E-5
— 72.6	 4.4
k 6.1	 0.4 11.6	 1.1,
p 1.68E-5
9.1	 0.8,
p 1.91E-3
7.9	 0.6,
p 2.38E-2
— 8.2	 1.7
n 22 7 8 9 6
DB fast inactivation
V0.5 (mV) #1 — — — — 71.2	 0.6 —
V0.5 (mV) #2 — — — — 31.4	 1.8 —
n 10
Slow inactivation
V0.5 (mV) 31.4	 1.8 — — — 41.4	 0.9,
p 4.00E-4
k 9.9	 0.6 — — — 11.3	 1.7 —
n 8 16
aThe table shows averaged parameters for channel activation, fast inactivation, and slow inactivation for WT andmutant NaV1.7 channels (W1775R, A1236E, L1831X, and L245V), as well as the1 /2 subunit. Fast inactivation values for
L245Vareunder a separate entry because of thedoubleBoltzmann fit (DB fast inactivation). Data aremean	 SEM.All values are comparedwith the averagedWTvalue.p value is given for comparisons that are deemed significantly different
( p 0.05). All single-parameter comparisons were tested using an unpaired two-way Student’s t test.
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mately contribute toward a loss of NaV1.7 function. Nonetheless,
our findings suggest that substantial, yet incomplete, block of
NaV1.7 andmodulation of channel activation/inactivation prop-
erties might be sufficient for pain therapy. Interestingly, a patient
has previously been reported with “partial congenital insensitiv-
ity to pain” who is a compound heterozygote for a 1 bp splice
donor deletion midway through the SCN9A gene and a C1719R
missense mutation (which maps upstream of the C-terminal in-
tracellular region) (Staud et al., 2011). Although no biophysical
analysis was performed, it was speculated by the authors that the
incomplete pain insensitivity seen in the patient may be consis-
tent with hypomorphic effects of one or both mutations. In con-
trast, the two families we describe appear to have complete pain
insensitivity (although one patient lacked any injuries to her lips,
tongue, or terminal digits often seen in other individuals with
congenitally inherited insensitivity to pain) but carried muta-
tions with at least some residual activity.
The C-terminal region of the voltage-gated sodium channel
family is well conserved, with an EF-hand and downstream IQ
motif annotated and verified in several NaV channels (Wingo et
al., 2004; Kubota et al., 2009;Miloushev et al., 2009). TheNaV1.7-
W1775 residue, which is mutated in CIP Family 2, is completely
conserved across all human NaV family members, and the anal-
ogous amino acid in the cardiac sodium channel, NaV1.5
(W1798) is known to be located within the first of 2 EF-hands.
EF-hands are helix-loop-helix structural domains found in a
large family of calciumbinding proteins. The EF-hand of voltage-
gated sodium channels is known to bind and stabilize the fast
inactivation gate and also binds with beta1 and beta3 subunits
(Spampanato et al., 2004; Cusdin et al., 2010). Mutations within
C-terminal EF-hands of human NaV channels have previously
been reported to cause diseases, such as potassium-aggravated
myonia and Long QT syndrome (Kubota et al., 2009; Glaaser et
al., 2012). Downstream of the EF-hand is a calmodulin-binding
IQ motif, which can modulate NaV currents (Mori et al., 2003;
Figure 2. Electrophysiological characterization of W1775R, A1236E, and L1831X in HEK293
cells. For each trace, averagedWT (black dash) and1/2 only (blue dash) traces are overlaid.
4
Comparisons to WT values are shown in Table 1. A, Left, Representative raw trace of W1775R
channel currents in response to the channel pulse protocol shown (activation). Right, Current–
voltage relationship of the peak activation currents normalized to cell size (pA/pF) for W1775R
(red). All traces were fitted with a Boltzmann equation (see Materials and Methods), where
V0.513.4	 1.3 mV, k7.5	 0.2, VRev 71.4	 4.9 mV, and IMax115.9	
15.0 pA/pF (n 7). B, Left, Representative raw trace of W1775R currents in response to a test
pulse to10 mV following a series of prepulses (protocol shown in inset; fast inactivation).
Right, Peak fast inactivation currents for W1775R (red) were normalized to the maximum
current and plotted against the prepulse potential used. Data were fitted with a Boltzmann
equation (see Materials and Methods), where V0.573.4	 2.2 mV and k 11.6	 1.1
(n7).C, Left, Representative raw trace of A1236E channel currents in response to the channel
pulse protocol. Right, Current–voltage relationship of the peak activation currents normalized
to cell size (pA/pF) for A1236E (red). All traces were fitted with a Boltzmann equation, where
V0.521.5	1.8mV, k7.3	0.4,VRev67.5	3.8mV, and IMax41.0	11.9
pA/pF (n 8). D, Left, Representative raw trace of A1236E currents in response to a test pulse
to10 mV following a series of prepulses as in B. Right, Peak fast inactivation currents for
A1236E (red) were normalized to the maximum current and plotted against the prepulse po-
tential used. Data were fitted with a Boltzmann, where V0.580.7	 1.3 mV and k
9.1	 0.8 (n 8). E, Left, Representative raw trace of L1831X channel currents in response to
the channel pulse protocol. Right, Current–voltage relationship of the peak activation currents
normalized to cell size (pA/pF) for L1831X (red). All traces were fitted with a Boltzmann equa-
tion, where V0.515.4	 1.8 mV, k7.6	 0.2, VRev 72.5	 5.3 mV, and IMax
103.3	14.0pA/pF (n9).F, Left, Representative raw traceof L1831X currents in response
to a test pulse to10mV following a series of prepulses. Right, Peak fast inactivation currents
for L1831X (red) were normalized to the maximum current and plotted against the prepulse
potential used. Data were fitted with a Boltzmann equation, where V0.582.2	 1.3 mV
and k 7.9	 0.6 (n 9).
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Reddy Chichili et al., 2013). In CIP Family 3, there is a truncating
mutation (L1831X) that causes deletion of this IQmotif from the
C terminus of the mutant NaV1.7 channel. The mutations re-
ported here highlight the importance of this region of the channel
for normal function.
In contrast to loss-of-function mutations, we also character-
ized the novel IEM-associated mutation, L245V. Until recently,
mutations in NaV1.7 that give rise to the hypersensitive pain con-
ditions IEM or PEPD have been functionally distinguished by
exhibiting either a hyperpolarizing shift in channel activation or a
Figure 3. Electrophysiological characterization of L245V in HEK293 cells. A, Left, Representative raw trace of L245V channel currents in response to the pulse protocol shown (activation). Right, Current–
voltagerelationshipofthepeakactivationcurrentsnormalizedtocellsize(pA/pF)forL245V(red).AveragedWT(blackdash)and1/2only(bluedash)tracesareoverlaid.All traceswerefittedwithaBoltzmann
equation (seeMaterials andMethods),whereV0.525.2	1.3mV, k4.9	0.4,VRev74.0	3.1mV, and IMax398	44.7 pA/pF (n16). Comparisons toWTvalues are shown in Table
1.B, Left,RepresentativerawtraceofL245Vcurrents inresponsetoatestpulseto10mVfollowingaseriesofprepulses (protocol shown; fast inactivation).Right,Peakfast inactivationcurrents forL245V(red)
werenormalizedtothemaximumcurrentandplottedagainsttheprepulsepotentialused.AveragedWT(blackdash)tracesareoverlaid.L245VtraceswerefittedwithadoubleBoltzmannequation(seeMaterials
andMethods),whereV0.5#171.2	0.6mVandV0.5#231.4	1.8mV(n14).ComparisonstoWTvaluesareshowninTable1.C, Left,Representativetail current tracesmeasuredat40mVfrom
wt, L245V, andA1632Eexpressing cellswithout (black) andwith (red) additionof4-peptide in the intracellular pipette solution. Thevoltage-stimulusprotocol is shownbelow.Right, ComparedwithWT, the
mutations L245V (top) andA1632E (bottom) cause a significant increase (p0.05) in tail current,measured as a fraction of thepeak activation current at voltages between80and20mV; therewasno
significant difference between L245V and A1632E or between the presence and absence of the4-peptide (two-way repeated-measures ANOVAwith Bonferroni post hoc; n 3–7).D, Remaining current
fraction (fraction ofmaximal peak current) at 50ms following a series of depolarizing voltage steps from100mV to 40mV. Inset, Averaged raw traces forWT (black) and L245V (red) in response to a single
voltagestep.*p0.05, individualcomparisons.p0.0026,WTversusL245Vgroupcomparison(two-wayrepeated-measuresANOVAwithBonferroniposthoc;n12–16).E,Peakslow-inactivationcurrents
were obtained for L245V (red) andWT (black) by applying an extended conditioning pulse (10 s) ranging from100mV to 30mVbefore stepping to120mV for 100ms to recover channels from the fast
inactivatedstatefollowedbyatestpulseat10mVfor20ms.Analysisshowspeakcurrents,normalizedtomaximalcurrent,obtainedatthefinal10mVtestpulseplottedagainsttheprepulsepotential.Data
are fittedwithaBoltzmannequation (seeMaterials andMethods)where: for theWTchannels,V0.531.43	1.8mVand k9.9	0.6; and for the L245V channels,V0.541.36	0.9mVand k
11.3	 1.7 (n 8–16). Comparisons are shown in Table 1. F, Rate of channel deactivation following a brief depolarizing step to 20mV (0.4ms) fromaholding potential of100mVbefore going to a final
potential ranging from120mV to40mV. Inset, Averaged raw traces forWT (black) and L245V (red)whena final voltage step to60mV is applied. *p0.05, individual comparisons.p0.0001,WT
versusL245Vgroupcomparison(two-wayrepeated-measuresANOVAwithBonferroniposthoc;n10–14).G,Analysisof inwardcurrentsduringadepolarizingrampstimulus from140mVto70mV. Inset,
AveragerawtracesforWT(black)andL245V(red)inresponsetothetestpulseapplied.*p0.05, individualcomparisons.p0.0266,WTversusL245Vgroupcomparison(two-wayrepeated-measuresANOVA
withBonferronipost hoc;n12–15).
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depolarizing shift in channel inactivation, respectively (Dib-Hajj
et al., 2013). Here, however, we showed that, unlike typical IEM-
associated mutations, L245V exhibited no shift in the voltage
dependence of channel activation. This is consistent with other
recently identified IEM-associated mutations. Eberhardt et al.
(2014) recently presented an IEM mutation (A1632T) that had
no change in channel activation but instead displayed a depolar-
izing shift in the voltage dependence of fast inactivation. The
apparent lack of a shift in channel activation was also evident
following the characterization of another IEM-associated muta-
tion, G616R (Choi et al., 2010). These findings therefore question
the validity of using a single marker to determine whether a mu-
tation is IEM or PEPD causing.
Despite there being no change in channel activation, L245V
did have changes in other gating characteristics, exhibiting in-
complete fast inactivation, a hyperpolarizing shift in slow inacti-
vation, a slowing of channel deactivation, the emergence of
persistent and associated tail currents, as well as increased ramp
currents. Understanding the relevance these changes have in pre-
determining an IEM or PEPD phenotype is difficult, as there is a
significant overlap between changes in NaV1.7 function and
pathogenesis; a slowing of channel deactivation, the presence of
persistent currents, as well as an increase in ramp current density
have all been previously associated with both IEM and PEPD
phenotypes (Lampert et al., 2006; Cheng et al., 2008, 2011; Choi
et al., 2011; Eberhardt et al., 2014). More recently, it has been
suggested that, in the absence of a shift in channel activation, the
presence of persistent and resurgent currents is likely a determi-
nant of whether a mutation is IEM or PEPD causing (Jarecki et
al., 2010; Theile et al., 2011; Eberhardt et al., 2014). This, how-
ever, is not supported by the significant persistent and associated
tail current presented here by L245V. Other electrophysiological
characteristic indicators that have been proposed to distinguish
IEM fromPEPD include the effects associatedmutations have on
neuronal physiology. It has been suggested that, although both
IEM and PEPD mutations lower the action potential threshold
and enhance action potential firing from sensory neurons when
overexpressed in DRG cultures, IEM-associated, but not PEPD-
associated, mutations typically cause a depolarization of the rest-
ing membrane potential (Dib-Hajj et al., 2010). Although not
directly studied here for L245V, Eberhardt et al. (2014) showed
that the IEM-associated A1632Tmutation did enhance excitabil-
ity but hadno effect on the restingmembrane potential of sensory
nerves. They concluded that the presence of persistent and resur-
gent currents is a characteristic hallmark for PEPD-associated
mutations; however, in contrast to this, we clearly observed per-
sistent currents for the IEM-associated L245V mutation, and a
recent publication showed that application of the sea-anemone
toxin ATX-II elicited resurgent currents predominantly in A-
fibers, associated with a pricking/tingling pain rather than the
burning pains reported in IEM and PEPD, which are thought to
be mostly C-fiber mediated (Klinger et al., 2012).
Phenotype prediction arising frommutations in SCN9A
Understanding the etiology of SCN9A-associated hyposensitive
and hypersensitive pain conditions is central to the development
of therapies aimed at treating these debilitating disorders.Within
recent years, much has been done to try and further understand
the role NaV1.7 channels have in the regulation of neuronal
excitability and pain; however, the current mismatch between
functional change and clinical phenotype suggests that
phenotype-prediction arising frommutations in SCN9A is com-
plex and unlikely to be determined by any single change in chan-
nel function. As presented here, both hyposensitive and
hypersensitive pain conditions arising frommutations in SCN9A
are likely to be determined by the overall functionality of NaV1.7
channels as described by all gating parameters in addition to the
size of the current passed.
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